Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Anavex Life Sciences Corp

AVXL ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.14

▼ -4.20%

Market Cap $105.67M · Vol 236.30K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$105.67M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

23.44

Momentum

Beta

1.25

vs Market

52W High

$7.90

85.57% below

52W Low

$1.13

0.88% above

Volume

236.30K

Avg 301.06K

P/B

8.13

Price-to-book

ROE

N/A

Return on equity

Free Float

98.29%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Anavex Life Sciences Corp (AVXL) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AVXL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.94%

-37.36%

-58.55%

-65.66%

YTD

-67.98%

-85.70%

-81.13%

-94.67%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-46,377,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-38.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	8.13
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	92.70M

Technical Indicators

50-Day SMA	$2.10
200-Day SMA	$3.07
RSI (14)	23.44
Beta	1.25
52-Week High	$7.90
52-Week Low	$1.13

Volume Today	236.30K
Avg Daily Volume (30D)	301.06K
Relative Volume	0.78x
Volatility (10D)	67.98
Volatility (30D)	74.49
Free Float	98.29%

Analyst Consensus

BUY

Current Price $1.14

Mean Target $20.00

52W Low$1.13 52W High$7.90

Current

Target

$1.13 $7.90

Current Analyst target

+1,654.39% upside potential · 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SLQWW6

ISINUS0327973006

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 23, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.22% ARGX.BR argenx SE -2.87% ARGX argenx SE -2.00% GMAB.CO Genmab A/S -5.47% GMAB Genmab A/S -3.75%

Company Profile

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.